Table 1.

Summary of BSG Service Standards.

Service standard	Target
All patients with suspected PBC should have an abdominal ultrasound as part of their baseline assessment.	90%
All patients should be offered first-line treatment with UDCA at 13–15 mg/kg/day.	90%
Individualised risk stratification using biochemical response indices is recommended following 1 year of UDCA therapy.	80%
All patients should be evaluated for the presence of symptoms, in particular fatigue and pruritus.	90%
All patients with a bilirubin >50 μmol/L or evidence of decompensated liver disease should be discussed with a hepatologist linked to a transplant programme (within 3 months).	90%
All patients should have a risk assessment for osteoporosis (within the last 5 years).	80%
When overlap with autoimmune hepatitis is suspected, liver biopsy with expert clinicopathological assessment should be undertaken to support diagnosis.	90%

BSG, British Society of Gastroenterology; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.